Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Clinical Therapeutics|February 7, 2018
Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO TrialSandra L Goss, Cheri E Klein, Ziyi Jin, et al.
Arthritis and Rheumatism|August 1, 2007
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled studyJohn C Davis, Dennis Revicki, Désirée M F van der Heijde, et al.
Arthritis Research & Therapy|August 26, 2009
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsDésirée van der Heijde, David Salonen, Barbara N Weissman, et al.
Annals of the Rheumatic Diseases|January 15, 2013
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 studyTsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, et al.
Arthritis Research & Therapy|August 19, 2009
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitisDésirée M van der Heijde, Dennis A Revicki, Katherine L Gooch, et al.
Rheumatology (Oxford, England)|January 21, 2014
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trialHisashi Yamanaka, Naoki Ishiguro, Tsutomu Takeuchi, et al.
Annals of the Rheumatic Diseases|November 18, 2017
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritisArthur Kavanaugh, Ronald F van Vollenhoven, Roy Fleischmann, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 13, 2022
Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa TrialFrank Buttgereit, Jacob Aelion, Bernadette Rojkovich, et al.
Lancet (London, England)|October 31, 2013
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialJosef S Smolen, Paul Emery, Roy Fleischmann, et al.
Clinical Rheumatology|March 20, 2008
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody statusArie E van der Bijl, Ferdinand C Breedveld, Christian E Antoni, et al.
Pageof 5